Protalix BioTherapeutics, Inc. - COM (PLX)

Q2 2023 13F Holders as of 30 Jun 2023

Type / Class
Equity / COM
Total 13F shares
8,968,409
Share change
+6,031,021
Total reported value
$17,889,394
Put/Call ratio
19%
Price per share
$2.00
Number of holders
65
Value change
+$11,985,895
Number of buys
53
Number of sells
13

Institutional Holders of Protalix BioTherapeutics, Inc. - COM (PLX) as of Q2 2023

As of 30 Jun 2023, Protalix BioTherapeutics, Inc. - COM (PLX) was held by 65 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 8,968,409 shares. The largest 10 holders included BlackRock Inc., STATE STREET CORP, RENAISSANCE TECHNOLOGIES LLC, MARSHALL WACE, LLP, GEODE CAPITAL MANAGEMENT, LLC, NORTHERN TRUST CORP, NATIONAL BANK OF CANADA /FI/, JANE STREET GROUP, LLC, Nuveen Asset Management, LLC, and VANGUARD GROUP INC. This page lists 65 institutional shareholders reporting positions in this security for the Q2 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.